◾ Because type 2 diabetes mellitus (T2DM) is a chronic, progressive disease, economic modeling over long time horizons is necessary in order to make informed decisions on the expected outcomes, costs, and quality-adjusted life-years (QALYs) of alternative treatment interventions. 1,2 Economic modeling is a widely used tool (endorsed by the American Diabetes Association [ADA] Consensus Panel, 2004 1 ) to predict the long-term impact of diabetes treatments ◾ Current treatments cannot halt disease progression, so most patients eventually require intensification of antihyperglycemic agent (AHA) therapy to meet HbA1c goals 3 ◾ Modeling treatment intensification over a long time horizon requires an algorithm to trigger changes in treatment. In empirical work, a number of different algorithms have been used, including: -Intensification modeled only via therapy cost increases over time 4 -Using a fixed time on agent prior to switching -Using different HbA1c thresholds to trigger a switch, including thresholds specified in guidelines (that may not reflect real-world behavior) or evidence-based thresholds that reflect intensification in the real world ◾ Assumptions surrounding treatment intensification used for modeling are important and potentially influential determinants of model outcomes
INTRODUCTION
◾ Because type 2 diabetes mellitus (T2DM) is a chronic, progressive disease, economic modeling over long time horizons is necessary in order to make informed decisions on the expected outcomes, costs, and quality-adjusted life-years (QALYs) of alternative treatment interventions. 1, 2 Economic modeling is a widely used tool (endorsed by the American Diabetes Association [ADA] Consensus Panel, 2004 1 ) to predict the long-term impact of diabetes treatments ◾ Current treatments cannot halt disease progression, so most patients eventually require intensification of antihyperglycemic agent (AHA) therapy to meet HbA1c goals 3 ◾ Modeling treatment intensification over a long time horizon requires an algorithm to trigger changes in treatment. In empirical work, a number of different algorithms have been used, including: -Intensification modeled only via therapy cost increases over time 4 -Using a fixed time on agent prior to switching -Using different HbA1c thresholds to trigger a switch, including thresholds specified in guidelines (that may not reflect real-world behavior) or evidence-based thresholds that reflect intensification in the real world ◾ Assumptions surrounding treatment intensification used for modeling are important and potentially influential determinants of model outcomes
OBJECTIVE
◾ To evaluate the impact of commonly used intensification assumptions on cost-effectiveness estimates using simulations of canagliflozin (CANA) versus glimepiride (GLIM) in patients with uncontrolled HbA1c on metformin (MET) in the US
METHODS
◾ Simulations in this analysis were based on results from a 52-week, randomized, double-blind, active-controlled, Phase 3 study that assessed the efficacy and safety of CANA 300 and 100 mg versus maximally tolerated GLIM (DIA3009) in patients with T2DM inadequately controlled with MET 5 -CANA, an agent that inhibits sodium glucose co-transporter 2 (SGLT2), works independently of insulin, thereby making it complementary to a range of other AHAs, including exogenous insulin; across Phase 3 studies, CANA has been associated with improved glycemic control and reductions in body weight and blood pressure (BP), with a low inherent risk of hypoglycemia 5-17 -In DIA3009, noninferiority in HbA1c lowering was observed with CANA versus GLIM, and CANA 300 mg was statistically superior to GLIM in HbA1c lowering over 52 weeks 5 ; CANA 100 and 300 mg also provided statistically significant reductions in body weight and modest reductions in BP compared with GLIM over 52 weeks. These results were sustained over 104 weeks 16 -The comparison to a sulfonylurea (SU; ie, GLIM) was chosen for this analysis because treatment intensification rules have particular importance with SUs due to their poor long-term durability. Additionally, in contrast to CANA, GLIM has been associated with weight gain and an increase in hypoglycemia
Simulation Overview
◾ A validated microsimulation model, the Economic and Health Outcomes Model of T2DM (ECHO-T2DM) 18 (Box 1), was used to simulate 30-year health and economic outcomes for hypothetical patients with T2DM treated with CANA 300 or 100 mg versus maximally titrated GLIM as second-line therapy for the treatment of T2DM
◾ Baseline characteristics for 1,000 cohorts of 2,000 unique patients with T2DM were randomly generated based on probability distributions taken from DIA3009 5 ◾ Patients entered the model and received CANA 300 or 100 mg or maximally titrated GLIM ◾ Treatment was intensified first by adding basal insulin, and subsequently by adding prandial insulin ◾ Treatment effects for CANA 300 and 100 mg and GLIM, including initial changes in HbA1c, SBP, lipids, and BMI, as well as AE rates, were sourced from DIA3009 ( Table 1) 5 ◾ Treatment effects (ie, HbA1c, rates of hypoglycemic events) for insulin were sourced from the literature 19 ◾ BP and lipids were treated according to the ADA guidelines 20 ◾ Changes in biomarkers affect the risk of micro-and macrovascular complications and mortality via established risk equations [21] [22] [23] Costs ◾ US-specific costs associated with health states and AEs were sourced from updated analyses according to a methodology previously described 26 ; unit cost assumptions for the CKD health states were taken from a Centers for Disease Control and Prevention study 27 ◾ Analy$ource was used for the prices of AHAs, antihypertensives, and antidyslipidemia agents 28 -CANA was priced at $9.64 and GLIM was priced at $0.41 per day (a 6 mg dose of GLIM was used, as this was the most common GLIM dose used in the clinical study) ◾ All costs used in the model were expressed in 2013 US dollars
Health-related Quality of Life
◾ Patient preferences for health are accounted for using QALY disutility weights (decrements in quality of life were associated with the negative impact of each health state) ◾ Disutility weights were applied to account for patient demographics (including advancing age and gender), clinical characteristics (including disease duration and BMI), the presence of micro-and macrovascular complications, and AEs 29-31
Outcomes ◾ A subset of outcomes that were generated by ECHO-T2DM are reported and include the following:
-Costs (total and by individual cost categories), life-years, and QALYs; all discounted at 3% per annum -Time to insulin rescue therapy -Incremental cost-effectiveness ratios (ICERs)
RESULTS

Treatment Intensification at HbA1c Thresholds
◾ The projected HbA1c values associated with treatment intensification at different HbA1c target thresholds are presented in Figure 1 -After initial lowering, HbA1c resumes its upward drift, putting patients at risk for needing rescue medication -The HbA1c curves converge over time, reaching a plateau; this reflects the simulated intensification of insulin to the prespecified treatment goal (HbA1c of 7.0% or 9.0%) ◾ ICERs for treatment strategies, starting with CANA 300 and 100 mg versus GLIM with insulin rescue at HbA1c >7.0%, were $22,106 and $29,032 per QALY gained, respectively ( Table 2) , largely driven by CANA's ability to keep HbA1c controlled longer, thus delaying insulin initiation -The largest drivers of QALY differences with CANA were lower rates of hypoglycemia and weight ◾ Delaying treatment intensification until HbA1c exceeded 9.0% was associated with higher costs and smaller QALY gains, which resulted in ICERs of $100,580 and $114,871 per QALY gained with CANA 300 and 100 mg, respectively
Treatment Intensification at Fixed Time Intervals
◾ The projected HbA1c values associated with treatment intensification at fixed time intervals are presented in Figure 2 ◾ Using a fixed (and equal) time on CANA and GLIM before initiating rescue therapy with insulin favored GLIM ( Table 3) , as the benefit of CANA in terms of HbA1c control over a longer time was eliminated with this assumption
No Treatment Intensification
◾ In the extreme case of no rescue therapy, HbA1c drifted upwards unabated (Figure 3) ◾ This led to artificial inflation of complication costs with CANA and GLIM; ICERs of $152,717 and $155,320 per QALY gained were seen with CANA 300 and 100 mg versus GLIM, respectively ( Table 4) DISCUSSION ◾ These simulation results illustrate that modeling assumptions about when (or if) to initiate rescue medication can have a large impact on the ICER, as modeling assumptions are typically not based on evidence and various options exist for rescue medication, ranging from additional oral AHAs to insulin. Health benefits are related to the space between the HbA1c time-paths for CANA and GLIM ◾ In the simulations when rescue medication was initiated at the time each hypothetical patient's HbA1c exceeded 7.0%, CANA 300 and 100 mg were associated with increased costs and QALYs compared with GLIM, with ICERs of <$30,000 per QALY gained, largely because inferior glycemic control with GLIM triggered earlier treatment intensification ◾ Costs and QALYs were also higher for both CANA doses versus GLIM with the less stringent HbA1c threshold of 9.0%. Because poor glycemic control was experienced in all treatment arms for long periods before rescue insulin therapy was initiated, many of the negative consequences of poor durability were delayed and reduced, yielding ICERs of just over $100,000 per QALY gained ◾ In the unrealistic (through frequently used) case in which treatment duration is not determined by treatment success of each agent separately, but instead by the same fixed duration of time, the situation was reversed. Because the better durability of both CANA doses disappeared in this scenario, the cost savings related to the lower acquisition price of GLIM was weighted heavily ◾ The elimination of rescue therapy altogether yielded much higher costs (since the occurrence of complications was artificially inflated) but more QALYs for both CANA doses, with ICERs of just over $150,000 per QALY gained 
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GENERAL SIMULATION CONDITIONS
Import user-de ned simulation run conditions
SIMULATION START
Set patient j = 1 and cycle t = 1
EXECUTE WEIGHT LOSS TREATMENT ALGORITHM (IF SPECIFIED)
Operates similarly to antihyperglycemia treatment algorithm (see below) 
Depression
• Probability of becoming depressed
Treatment for other comorbidities
The macrovascular, retinopathy and neuropathy, CKD, hypoglycemic event rates, kidney-related AEs, peripheral edema, osteoporosis-related fractures, depression, antihypertension, and antidyslipidemia modules are evaluated in random order each cycle. "Events" within each module are also evaluated in random order. 1. Apply agents speci ed as ongoing at simulation baseline if cycle t = 1 (optional) 2. Apply initial agents if cycle t = 1 3. Determine HbA1c treatment intensi cation target thresholds 4. Adjust antihyperglycemia treatment if necessary and apply treatment effects (adjusted for compliance and eGFR level, as speci ed) 5. Determine drug-speci c probability that patient stops smoking 6. Adjust for both treatment effects related to new cases of noncompliance (related to occurrence of hypoglycemia in previous cycle) and for rebound related to discontinued agents 7. Apply drug-speci c hazard rates and relative risks for AEs Generate initial patient characteristics for j = 1 to J patients (patient heterogeneity) Box 1. ECHO-T2DM model structure. 18 eGFR, estimated glomerular filtration rate; AE, adverse event; CKD, chronic kidney disease; UKPDS, United Kingdom Prospective Diabetes Study; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-release Controlled Evaluation; NDR, National Diabetes Registry; IHD, ischemic heart disease; MI, myocardial infarction; CHF, congestive heart failure; CVD, cardiovascular disease; BDR, background diabetic retinopathy; PDR, proliferative diabetic retinopathy; ME, macular edema; PVD, peripheral vascular disease; LEA, lower extremity amputation; UTI, urinary tract infection; SBP, systolic BP; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index.
ECHO-T2DM is a stochastic, microsimulation, annual cycle model based on Markov health states that reflect the key elements of T2DM and its treatment.
◾ It draws cohorts of hypothetical patients from distributions based on initial patient demographics (eg, age, gender), disease characteristics (eg, duration of disease, HbA1c, BMI), and comorbidities ◾ It allows user-defined treatment algorithm of drug intensification that is designed to control blood glucose and to treat hypertension, dyslipidemia, and excessive weight ◾ Patient biomarker values (ie, HbA1c, SBP, BMI, lipids) are updated annually to reflect drug-specific treatment effects and "drifts" in these biomarkers over time due to the progressive nature of the disease ◾ Risk functions are used to predict event rates over time (eg, MI, stroke, amputation, ME) and are driven by changes in biomarkers (ie, HbA1c, SBP, BMI) ◾ Treatment-related AEs and tolerability can lead to discontinuation ◾ It allows the user to assign costs for disease-related complications (initial and annual state), AEs, treatment interventions, and quality-of-life weights to reflect patient preferences for health states ◾ All costs, life-years, and QALYs are aggregated for each patient at the end of the time horizon or death An electronic version of the poster can be viewed by scanning the QR code. The QR code is intended to provide scientific information for individual reference. The PDF should not be altered or reproduced in any way.
